Cite
HARVARD Citation
Burmester, G. et al. (n.d.). FRI0216 Results of a longitudinal review of pulmonary function and safety data in a phase iib clinical programme testing granulocyte-macrophage colony-stimulating factor (GM–CSF) receptor antagonist mavrilimumab for treatment of rheumatoid arthritis (RA). Annals of the rheumatic diseases. pp. 564-565. [Online].